High-Intensity, Dynamic-stability Gait Training in People With Multiple Sclerosis
Part of paid clinical trials in Indianapolis, Indiana.
- Sponsor
- Marquette University
- Study ID
- NCT05735691
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 75 Years
- Healthy Volunteers
- Not accepted
Interventions
- High-Intensity Treadmill Training — PROCEDUREParticipants will walk on a treadmill at a speed that produces 70-80% of age-adjusted heart rate reserve or a rating of perceived exertion of 17/20. A total of 30, one hour sessions will be conducted. Training will be conducted in 10 minute bouts, with 2-3 minutes rest between bouts.
- Treadmill Training with Perturbations — PROCEDUREParticipants will walk on a treadmill and a perturbation of the treadmill will be produced every 20s. Perturbations will randomly occur in the forward, backward, right or left directions, with a perturbation size set to 80% of stability threshold. A total of 30, one hour sessions will be conducted. Training will be conducted in 10 minute bouts with 2-3 minutes rest between bouts.
- Standard Treadmill Training — PROCEDUREParticipants will walk on a treadmill at a speed that produces 30-40% of age-adjusted heart rate reserve. A total of 30, one hour sessions will be conducted. Training will be conducted in 10 minute bouts, with 2-3 minutes rest between bouts.
Study Details
The goal of this clinical trial is to improve walking speed, balance, and walking in the community for people with multiple sclerosis. This trial involves intense exercise combined with walking on a shaky treadmill. Walking on a shaky treadmill helps to practice balance and intense exercise promotes the ability to walk faster and farther. In this study, participants will train with a combination of high or low intensity, and with a stable or shaky treadmill. Walking speed and endurance, balance while walking and the number of steps taken in the community will be measured before, half way through the training (15 sessions), after training (30 sessions) and six months after training.
Key Dates
- Start date
- Jan 1, 2023
- Status verified
- Jun 2024
- Primary completion
- Jun 30, 2027
- Completion
- Jun 30, 2027
Study Design
- Enrollment
- 150 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- FACTORIAL
- Primary purpose
- TREATMENT
Arms
- Experimental: High-Intensity With Pertubations30 sessions of high-intensity treadmill training will be conducted. Perturbations that disrupt balance will be applied during the training.
- Experimental: High-Intensity No Perturbations30 sessions of high-intensity treadmill training will be conducted on a stable treadmill.
- Experimental: Moderate-Intensity With Perturbations30 sessions of moderate-intensity treadmill training will be conducted. Perturbations that disrupt balance will be applied during the training.
- Active Comparator: Moderate-Intensity No Perturbations30 sessions of moderate-intensity treadmill training will be conducted on a stable treadmill.
Primary Outcome Measure
Changes in Timed 25-foot walk test [ Time Frame: Before training, 5-6 weeks after training begins, 1-2 weeks after all training sessions, 6 months after all training sessions ]
Central Contacts
- Brian D Schmit, PhD4142886125
Locations (2)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Rehabilitation Hospital of Indiana | Indianapolis | Indiana | 46254 | Thomas G Hornby, PhD |
| Marquette University | Milwaukee | Wisconsin | 53233 |
Find similar trials in Indianapolis, IN
Related Studies
- Macromolecular Imaging of White and Gray Matter Pathology in Multiple SclerosisEnrolling By Invitation · University of Wisconsin, Madison · Madison, Wisconsin
- Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation ResearchRecruiting · Brain Inflammation Collaborative · Delafield, Wisconsin
- A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)PHASE1 · Recruiting · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Birmingham, Alabama
- A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)Recruiting · TG Therapeutics, Inc. · Birmingham, Alabama